Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMLX
SellHot AirAmylyx Pharmaceuticals, Inc. · Healthcare · United States · $3.9B · Avg Vol: $104M/d
COMPANY DESCRIPTION
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for neurodegenerative diseases, most notably Amyotrophic Lateral Sclerosis (ALS). The company's competitive moat is derived from its innovative drug candidates addressing high unmet medical needs and the regulatory approvals achieved for its key product in major markets. It focuses on improving the lives of patients with devastating neurological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 22.2M | 380.8M | 87.4M | 0 | 98.3% | — | — | 28.2M | -31.4% |
| EPS | -1.59 | -3.39 | 0.73 | -4.43 | -1.53 | — | -1.41 | -1.50 | -1.15 | — |
| Shares | — | 66.5M | 67.7M | 68.6M | 109.9M | +65.2% | 111.4M | — | — | — |
| Debt | — | 6.3M | 4.2M | 2.0M | 6.0M | -1.7% | 5.3M | — | — | — |
| Equity | — | 340.6M | 433.4M | 164.8M | 305.3M | -3.6% | — | — | — | — |
| Op CF | — | -179.9M | 11.9M | -167.6M | -123.3M | — | -126.6M | — | — | — |
| Inv CF | — | -239.0M | 92.1M | 75.7M | 14.0M | — | — | — | — | — |
| Fin CF | — | 431.8M | 3.5M | 0.3M | 257.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMLX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc.(you) | $3.9B | 30 | Sell |
| HIMS | Hims & Hers Health, Inc. | $6.7B | 26 | Sell |
| HROW | Harrow, Inc. | $1.5B | 29 | Sell |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | 43 | Hold |
| CURA.TO | Curaleaf Holdings, Inc. | $2.6B | 48 | Hold |
| GLAS | Glass House Brands Inc. | $931M | 18 | Strong Sell |
| VREO.CN | Vireo Growth Inc. | $552M | 33 | Sell |
| LQDA | Liquidia Corporation | $6.1B | 64 | Hold |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%